BRTX
Price
$1.72
Change
-$0.08 (-4.44%)
Updated
Apr 4, 02:05 PM (EDT)
Capitalization
12.66M
46 days until earnings call
URGN
Price
$10.12
Change
-$0.41 (-3.89%)
Updated
Apr 4, 04:40 PM (EDT)
Capitalization
485.83M
34 days until earnings call
Ad is loading...

BRTX vs URGN

Header iconBRTX vs URGN Comparison
Open Charts BRTX vs URGNBanner chart's image
BioRestorative Therapies
Price$1.72
Change-$0.08 (-4.44%)
Volume$1K
Capitalization12.66M
UroGen Pharma
Price$10.12
Change-$0.41 (-3.89%)
Volume$500
Capitalization485.83M
BRTX vs URGN Comparison Chart
Loading...
BRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BRTX vs. URGN commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BRTX is a Hold and URGN is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (BRTX: $1.80 vs. URGN: $10.53)
Brand notoriety: BRTX and URGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BRTX: 5% vs. URGN: 147%
Market capitalization -- BRTX: $12.66M vs. URGN: $485.83M
BRTX [@Biotechnology] is valued at $12.66M. URGN’s [@Biotechnology] market capitalization is $485.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BRTX’s FA Score shows that 0 FA rating(s) are green whileURGN’s FA Score has 0 green FA rating(s).

  • BRTX’s FA Score: 0 green, 5 red.
  • URGN’s FA Score: 0 green, 5 red.
According to our system of comparison, BRTX is a better buy in the long-term than URGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BRTX’s TA Score shows that 4 TA indicator(s) are bullish while URGN’s TA Score has 4 bullish TA indicator(s).

  • BRTX’s TA Score: 4 bullish, 6 bearish.
  • URGN’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both BRTX and URGN are a bad buy in the short-term.

Price Growth

BRTX (@Biotechnology) experienced а -1.64% price change this week, while URGN (@Biotechnology) price change was -8.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.30%. For the same industry, the average monthly price growth was -17.15%, and the average quarterly price growth was -18.93%.

Reported Earning Dates

BRTX is expected to report earnings on May 20, 2025.

URGN is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-11.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
URGN($486M) has a higher market cap than BRTX($12.7M). BRTX YTD gains are higher at: 25.874 vs. URGN (-1.127). BRTX has higher annual earnings (EBITDA): -11.9M vs. URGN (-110.34M). URGN has more cash in the bank: 237M vs. BRTX (13.1M). BRTX has less debt than URGN: BRTX (42.4K) vs URGN (123M). URGN has higher revenues than BRTX: URGN (90.4M) vs BRTX (377K).
BRTXURGNBRTX / URGN
Capitalization12.7M486M3%
EBITDA-11.9M-110.34M11%
Gain YTD25.874-1.127-2,296%
P/E RatioN/AN/A-
Revenue377K90.4M0%
Total Cash13.1M237M6%
Total Debt42.4K123M0%
FUNDAMENTALS RATINGS
BRTX vs URGN: Fundamental Ratings
BRTX
URGN
OUTLOOK RATING
1..100
1879
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
77
Overvalued
PROFIT vs RISK RATING
1..100
99100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3847
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BRTX's Valuation (39) in the null industry is somewhat better than the same rating for URGN (77) in the Biotechnology industry. This means that BRTX’s stock grew somewhat faster than URGN’s over the last 12 months.

BRTX's Profit vs Risk Rating (99) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that BRTX’s stock grew similarly to URGN’s over the last 12 months.

BRTX's SMR Rating (99) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that BRTX’s stock grew similarly to URGN’s over the last 12 months.

BRTX's Price Growth Rating (38) in the null industry is in the same range as URGN (47) in the Biotechnology industry. This means that BRTX’s stock grew similarly to URGN’s over the last 12 months.

BRTX's P/E Growth Rating (100) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that BRTX’s stock grew similarly to URGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BRTXURGN
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 12 days ago
88%
Bullish Trend 15 days ago
82%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 4 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Ad is loading...
BRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCCVX32.97N/A
N/A
Fidelity Advisor Convertible Secs C
MRFIX57.60N/A
N/A
MFS Research I
PQNAX25.54N/A
N/A
Virtus NFJ Mid-Cap Value A
GALPX21.36N/A
N/A
Goldman Sachs U.S. Equity ESG P
FEGKX13.39N/A
N/A
Fidelity Equity Growth K6

BRTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BRTX has been loosely correlated with TCRT. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if BRTX jumps, then TCRT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BRTX
1D Price
Change %
BRTX100%
-2.70%
TCRT - BRTX
33%
Loosely correlated
+50.71%
ETNB - BRTX
30%
Poorly correlated
-4.59%
URGN - BRTX
30%
Poorly correlated
-5.98%
CERO - BRTX
29%
Poorly correlated
-4.12%
GRCE - BRTX
28%
Poorly correlated
-4.76%
More